Moderna Email Format

Biotechnology Research
1,001-2,500 employees
Cambridge, MA, USA

Moderna is a biotechnology company pioneering mRNA medicine to develop vaccines and therapeutics for infectious diseases, cancer, and rare diseases worldwide.

Find contacts at Moderna

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@modernatx.com

Company Overview

Industry
Biotechnology Research
Founded
2010
Headquarters
Cambridge, MA, USA
Revenue
$5B-$10B
FUNDING Stage
Public
Key Executives
Stéphane Bancel (Chief Executive Officer), Jamey Mock (Chief Financial Officer), Jerh Collins (Chief Technical Operations and Quality Officer)

Tech Stack

AWS

Cloud

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Moderna?

Moderna uses the first.last format, so Jane Smith would be jane.smith@modernatx.com.

What approved commercial vaccines does Moderna sell in 2026?

Moderna has three commercially approved products in 2026: Spikevax (COVID-19 vaccine), mNEXSPIKE (next-generation COVID-19 vaccine), and mRESVIA, its mRNA-based RSV vaccine for adults. Tools like Clay can help you find the right Moderna contact to discuss these products.

Where is Moderna headquartered and what does the company focus on?

Moderna is headquartered at 325 Binney Street in Cambridge, Massachusetts, and focuses on developing mRNA medicines across infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune disease.

How far along is Moderna's personalized cancer vaccine program in 2026?

Moderna's personalized cancer vaccine intismeran autogene, developed in collaboration with Merck, is in a fully enrolled Phase 3 trial called INTerpath-001 for adjuvant melanoma, with five-year Phase 2b data published in early 2026 showing a sustained 49% reduction in recurrence risk.

Who leads Moderna's scientific and research efforts in 2026?

Stephen Hoge, M.D. serves as President of Moderna in 2026, overseeing scientific research, clinical development, and the commercial organization, while Stéphane Bancel remains Chief Executive Officer. Moderna was co-founded in 2010 by Noubar Afeyan and others through Flagship Pioneering.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles